The aim of this novel and ambitious project is to develop potent new vaccines with potential to prevent recurrence of HER2 positive breast cancer. This is made possible through the team’s prior experience and the availability of partially tested vaccines, cell lines and animal strains and through collaboration. It is expected that the differing chemical structures of the vaccines will elicit and prime, immune responses in different tissue compartments, (lung, stomach and liver). Metastasis is a devastating complication of breast cancer, and tumours over-expressing human epidermal growth factor receptor 2 (HER2) carry higher risk.

FIRST NAMED INVESTIGATOR: Dr Robert Weinkove
HOST INVESTIGATOR: Malaghan Institute of Medical Research